Method for preventing and/or treating insulin resistance
View Patent ↗Described is the use of Eubacterium hallii et rel. and/or Alcaligenes faecalis et rel., as well as pharmaceutical, food, or feed compositions comprising these bacteria as a medicament, in particular, for preventing and/or treating insulin resistance and/or insulin resistance-related complications such as metabolic syndrome, dyslipidemia and type 2 diabetes mellitus, as well as insulin resistance in endocrine diseases (e.g., obese subjects with type 1 diabetes mellitus, Cushing's disease and lipodystrophy syndromes. Also described is a method for preventing and/or treating insulin resistance and/or insulin resistance-related complications such as dyslipidemia and type 2 diabetes mellitus as well as insulin resistance in endocrine diseases (e.g., obese subjects with type 1 diabetes mellitus, Cushing's disease and lipodystrophy syndromes) in a subject in need thereof, the method comprising the step of increasing the level of Eubacterium hallii et rel. and/or Alcaligenes faecalis et rel. in the small intestine.
1. A method of reducing an insulin resistance-related complication in an obese subject diagnosed as suffering from the insulin resistance-related complication, the method comprising:
administering to the subject an amount of Eubacterium hallii et relatives and Alcaligenes faecalis et relatives effective to reduce the insulin resistance-related complication.
2. The method according to claim 1 , wherein the insulin resistance-related complication is selected from the group consisting of metabolic syndrome, dyslipidemia, type 2 diabetes mellitus, insulin resistance in endocrine disease, and combinations of any thereof.
3. The method according to claim 1 , wherein the E. hallii et rel. and A. faecalis et rel. are administered as a composition comprising both the E. hallii et rel. and A. faecalis et rel.
4. The method according to claim 3 , wherein the insulin resistance-related condition is selected from the group consisting of metabolic syndrome, dyslipidemia, type 2 diabetes mellitus, insulin resistance in endocrine disease, and combinations of any thereof.
5. The method according to claim 2 , wherein the insulin resistance-related condition comprises insulin resistance in endocrine disease in an obese subject having a disease selected from the group consisting of type 1 diabetes mellitus, Cushing's disease, and lipodystrophy syndrome.
6. The method according to claim 4 , wherein the insulin resistance-related condition comprises insulin resistance in endocrine disease in an obese subject having a disease selected from the group consisting of type 1 diabetes mellitus, Cushing's disease, and lipodystrophy syndrome.